Lipid profiles and serum Visfatin concentrations in patients with type II diabetes in comparison with healthy controls

International Journal of Preventive Medicine

Volumn 3, Issue 5, 2012, Pages 326-331

  Hajianfar, Hossein ^a   Bahonar, Ahmad ^b   Entezari, Mohammad Hassan ^c   Askari, Gholamreza ^c   Yazdani, Maedeh ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Lipid profile; Type II diabetes; Visfatin

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PHYSICAL ACTIVITY; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84862023845     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta cell function: Potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002;32:s24-34.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995--2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
3. Jung CH, Rhee EJ, Kim SY, Shin HS, Kim BJ, Sung KC, et al. Associations between two single nucleotide polymorphisms of adiponection gene and coronary artery diseases. Endocr J 2006;53:671-7.
4. Kleinman JC. Mortality among diabetics in - a national sample. Am J Epidemiol 1988;128:389-401.
5. Fantuzzi G. Adipose tissue, adipokin and infammation. J Allergy Clin Immunol 2005;115:911-919; quiz 920.
6. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishmoto K, et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005;21:307:366-7.
7. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/ pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295-9.
8. Imai S. Nicotinamide phosphoribosyltransferase (Nampt): A link between NAD biology, metabolism, and diseases. Curr Pharm Des 2009;15:20-8.
9. Bemdt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911-2916.
10. Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM, et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) infuence plasma insulin levels. Diabetes 2006;55:2896-902.
11. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ, et al. Human visfatin expression: Relationship to insulin sensitivity, intramyocellular lipids and inflammation. J Clin Endocrinol Metab 2007;92:666-72.
12. Haider DG, Pleiner J, Francesconi M, Wiesinger GF, Müller M, Wolzt M. Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab 2006;91:4702-4.
13. Betowski J. Apelin and visfatin: unique "benefcial" adipokines upregulated in obesity. Med Sci Monit 2006;12:RA112-119.
14. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30.
15. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006;91:1578-81.
16. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006;49:1909-14.
17. Revollo JR, Komer A, Mills KF, Satoh A, Wang T, Garten A, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007;6:363-75.
18. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007;23:164-70.
19. Ferris WF, Naran NH, Crowther NJ, Rheeder P, van der Merwe L, Chetty N. The relationship between insulin sensitivity and serum adiponectin levels in three population groups. Horm Metab Res 2005;37:695-701.
20. Matsuzawa Y. Therapy insight: Adipokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006;3:3542.
21. Haffner SM, Gingerich RL, Miettinen H, Stern MP. Leptin concentrations in relation to overall adiposity and regional body fat distribution in Mexican Americans. Int J Obes Relat Metab Disord 1996;20:904-8.
22. Hajianfar H, Hosseinzadeh MJ, Bahonar A, Mohammad K, Askari GR, Entezari MH, et al. The effect of omega3 on the serum visfatin concentration in patient with type II diabetes. JMRS 2011;16:490-5.
23. Tanaka M, Nozaki M, Fukuhara A, Segawa K, Aoki N, Matsuda M, et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun 2007;359:194-201.
24. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre B-cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006;91:3165-70.
25. Goldberg IJ. Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 2001;86:965-71.
26. Gotto A, Pownall H. The Manual of Lipid Disorders: Reducing the Risk for Coronary Heart Disease. 3rd ed. New York: Lippincott Williams and Wilkins; 2003.
27. Sadeghi M, Roohafza H, Shirani S, Poormoghadas M, Kelishadi R, Baghaii A, et al. Diabetes and associated cardiovascular risk factors in Iran: The Isfahan Healthy Heart Programme. Ann Acad Med Singapore 2007;36:175-80.
28. Duan Y, Wu Z, Liu B. Relation of plasma glucose levels to serum lipids and apolipoproteins levels in middle and old age males. Hua Xi Yi Ke Da Xue Xue Bao 2001;32:382-4.
29. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.